United States - English - NLM (National Library of Medicine)

american regent, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 5 mg in 1 ml - nitroglycerin injection is indicated for treatment of peri-operative hypertension; for control of congestive heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and β -blockers; and for induction of intraoperative hypotension. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin injection is contraindicated in patients who are allergic to it. in patients with pericardial tamponade, restrictive cardiomyopathy, or constrictive pericarditis, cardiac output is dependent upon venous return. intravenous nitroglycerin is contraindicated in patients with these conditions.

United States - English - NLM (National Library of Medicine)

preferred pharmacetucials inc. - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), trimethoprim sulfate (unii: e377mf8eq8) (trimethoprim - unii:an164j8y0x) - polymyxin b 10000 [usp'u] in 1 ml - polymyxin b sulfate and trimethoprim ophthalmic solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: staphylococcus aureus, staphylococcus epidermidis, streptococcus pneumoniae, streptococcus viridans, haemophilus influenzae and pseudomonas aeruginosa. * *efficacy for this organism in this organ system was studied in fewer than 10 infections. polymyxin b sulfate and trimethoprim ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

kremers urban pharmaceuticals inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 20.8 mg - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product.

United States - English - NLM (National Library of Medicine)

avkare - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 2.5 mg - nitroglycerin extended-release capsules are indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of oral nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it.

United States - English - NLM (National Library of Medicine)

gland pharma limited - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - polymyxin b 500000 - acute infections caused by susceptible strains of pseudomonas aeruginosa polymyxin b sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of ps. aeruginosa. it may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of ps. aeruginosa . it may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: h. influenzae , specifically meningeal infections. escherichia coli , specifically urinary tract infections. aerobacter aerogenes , specifically bacteremia. klebsiella pneumoniae , specifically bacteremia. note: in meningeal infections, polymyxin b sulfate should be administered only by the intrathecal route. to reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin b and other antibacterial drugs, polymyxin b should be used

United States - English - NLM (National Library of Medicine)

eugia us llc - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - polymyxin b 500000 [usp'u] - acute infections caused by susceptible strains of pseudomonas aeruginosa. polymyxin b sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of ps. aeruginosa . it may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of ps. aeruginosa . it may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: h influenzae , specifically meningeal infections. escherichia coli , specifically urinary tract infections. aerobacter aerogenes , specifically bacteremia. klebsiella pneumoniae , specifically bacteremia. note: in meningeal infections, polymyxin b sulfate should be administered only by the intrathecal route. to reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin b and other antibacterial drugs,

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.2 mg in 1 h - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product. do not use nitroglycerin transdermal systems in patients who are taking phosphodiesterase inhibitors (such as sildenafil, tadalafil, or vardenafil) for erectile dysfunction or pulmonary arterial hypertension. concomitant use can cause severe drops in blood pressure. do not use nitroglycerin transdermal systems in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 2.5 mg in 1 d - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.1 mg in 1 h - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product. do not use nitroglycerin transdermal systems in patients who are taking phosphodiesterase inhibitors (such as sildenafil, tadalafil, or vardenafil) for erectile dysfunction or pulmonary arterial hypertension. concomitant use can cause severe drops in blood pressure. do not use nitroglycerin transdermal systems in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.2 mg in 1 h - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product. do not use nitroglycerin transdermal systems in patients who are taking phosphodiesterase inhibitors (such as sildenafil, tadalafil, or vardenafil) for erectile dysfunction or pulmonary arterial hypertension. concomitant use can cause severe drops in blood pressure. do not use nitroglycerin transdermal systems in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.